Methods for treating diabetic kidney disease and glomerular disease
AssigneeNephris SrL
InventorsPaolo Fiorina, Francesca D'Addio
Life of this patent
Estimating the term…
Abstract
Methods are provided for delaying onset or progression of kidney damage, or treating kidney disease, in a subject who has type 1 diabetes or type 2 diabetes or glomerular disease. The methods comprise administering to a subject with type 1 or type 2 diabetes or glomerular disease an effective amount of an agent capable of inhibiting NBL1 activity, and in particular, capable of inhibiting NBL1-mediated toxicity of human podocytes. In some embodiments, the agent is an antibody capable of binding to human NBL1.
Claims28
An antibody or antigen binding fragment thereof comprising three heavy chain variable region (VH) CDRs and three light chain variable region (VL) CDRs, wherein
- (a) the three VH CDRs respectively have the sequences of SEQ ID NO:93, SEQ ID NO:98, and SEQ ID NO:103, and
- (b) the three VL CDRs respectively have the sequences of SEQ ID NO:108, SEQ ID NO:113, and SEQ ID NO:118;
- wherein the antibody or antigen binding fragment thereof is capable of binding to neuroblastoma suppressor of tumorgenicity 1 (NBL1).
A method for treating or delaying onset or progression of kidney damage in a subject who has type 1 or type 2 diabetes or a glomerular disease, the method comprising:
- administering to the subject an effective amount of an antibody or antigen binding fragment thereof comprising three heavy chain variable region (VH) CDRs and three light chain variable region (VL) CDRs, wherein
- (a) the three VH CDRs respectively have the sequences of SEQ ID NO:93, SEQ ID NO:98, and SEQ ID NO:103, and
- (b) the three VL CDRs respectively have the sequences of SEQ ID NO:108, SEQ ID NO:113, and SEQ ID NO:118;
- and
- wherein the antibody or antigen binding fragment thereof is capable of inhibiting neuroblastoma suppressor of tumorgenicity 1 (NBL1) activity.
Dependencies are inferred from the claim text.